Atazanavir-associated QT interval prolongation and torsades de points in a patient with liver cirrhosis: A rare but serious complication

Infectious Diseases in Clinical Practice

Volumn 19, Issue 3, 2011, Pages 226-228

  Dabiesingh, Devindra S ^a,b   Psevdos, George ^b   Sharp, Victoria L ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

atazanavir; QT interval; torsades

Indexed keywords

ATAZANAVIR; LAMIVUDINE PLUS ZIDOVUDINE; OXYCODONE;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETHALITY; LIVER CIRRHOSIS; MALE; PATIENT COMPLIANCE; QT PROLONGATION; RARE DISEASE; TORSADE DES POINTES; VIRUS INHIBITION;

EID: 79955635833     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3181fc6e51     Document Type: Article

References (13)

1. Roden DM. A practical approach to torsade de pointes. Clin Cardiol. 1997;20:285-290. (Pubitemid 27120167)
2. Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 1995;122:701-714.
3. Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther. 2003;1:403-413. (Pubitemid 38855105)
4. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis. 2007;44:e67-e68.
5. Gallagher DP, Kieran J, Sheehan G, et al. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis. 2008;47:e36-e38. (Pubitemid 352009380)
6. Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther. 2009;17(6):e193-e201.
7. Charbit B, Rosier A, Bollens D, et al. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol. 2009;67(1):76-82.
8. Anson B, Weaver J, Ackerman M, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365(9460):682-686. (Pubitemid 40260891)
9. Sarapa N, Nickens DJ, Raber SR, et al. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther. 2008;83(1): 153-159.
10. Damle B, Fosser C, Ito K, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol. 2009;49(3):291-300.
11. Fanoe S, Jensen GB, Sjøgren P, et al. Oxycodone is associated with dose-dependent QTc prolongation and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009;67:172-179.
12. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy. 2003;23:802-805. (Pubitemid 36629083)
13. Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7:317-322. (Pubitemid 43805692)